Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Elanco Animal Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Elanco Animal Health's regulatory disclosures and financial reporting.
Elanco Animal Health officer Ellen de Brabander reported equity compensation changes. She received an employee stock option for 51,819 shares and grants of 67,564 and 25,360 shares of common stock, all at a price of $0.00 per share. A separate 46,278-share disposition at $26.40 per share covered tax obligations. The footnotes state that both the restricted stock units and stock options vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health executive Timothy J. Bettington reported multiple equity transactions on March 1, 2026. He received an employee stock option grant for 19,350 options and several grants of common stock totaling 55,792 shares as awards. A separate transaction disposed of 18,098 common shares at $26.40 per share to cover tax withholding. The restricted stock units and stock options vest in three equal installments on March 1, 2027, March 1, 2028, and March 1, 2029.
Elanco Animal Health reported that officer Rajeev A. Modi acquired a grant of 56.6301 deferred stock units on Company stock, valued at $24.98 per unit. After this award, his direct holdings in these deferred stock units total 7,651.0914 units.
Each deferred stock unit represents the right to receive either one share of Elanco common stock or the cash equivalent. According to the company’s Executive Deferral and Stock Match Plan, these units are scheduled to settle in cash or shares after employment ends or in a specified future year.
Elanco Animal Health President and CEO Jeffrey N. Simmons reported an acquisition of deferred stock units as part of his compensation. He received 110.8583 deferred stock units on Company common stock at a reference price of $24.98 per unit, described as a grant or award. After this award, his direct holdings of deferred stock units total 19,179.7639 units. Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent, and they settle in cash or shares following termination of employment or in a specified future year under the Executive Deferral and Stock Match Plan.
VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 7.6217 deferred stock units at a reference price of $24.98 per unit. This award increases his directly held deferred stock units to 31.0919. Each unit represents the right to receive one share of Elanco common stock or the cash equivalent, settling after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Incorporated provides its annual report for the year ended December 31, 2025, detailing its global animal health business focused on pet and farm animal products sold in more than 90 countries. The company highlights a diversified portfolio where its top five product families, including Advantage, Seresto, Credelio, Rumensin and Maxiban/Monteban, contribute about 38% of total revenue, with Advantage alone at roughly 10%. Elanco reports significant innovation efforts, with recent approvals and launches such as Bovaer for methane reduction in dairy cattle, Zenrelia and Credelio Quattro for dogs, and Befrena, an anti-IL31 monoclonal antibody for canine dermatitis expected to launch in 2026. R&D expense was $368 million in 2025, supported by over 1,000 R&D and regulatory employees and a global network of centers. The company describes a major restructuring plan approved in December 2025 that includes $155 million of charges in 2025, planned site closures in Germany and Kansas, and an expected net headcount reduction of about 300 employees. Elanco also outlines extensive regulatory, manufacturing, IT, climate and market risks, including patent expirations, generic competition, antibiotic usage pressures and shifting distribution toward e‑commerce.
Elanco Animal Health reported strong growth for the fourth quarter of 2025, with revenue of $1,144 million, up 12% on a reported basis and 9% in organic constant currency. Pet Health and Farm Animal both grew double digits, helped by new products like Credelio Quattro, Zenrelia and Experior.
For full year 2025, revenue rose 6% to $4,715 million and organic constant currency growth was 7%. Despite this, Elanco posted a reported net loss of $232 million, largely reflecting amortization and restructuring, while adjusted net income was $473 million and adjusted EBITDA was $901 million, a 19.2% margin.
The company issued 2026 guidance for revenue of $4,950–$5,020 million, implying 4%–6% organic constant currency growth, adjusted EBITDA of $955–$985 million and adjusted EPS of $1.00–$1.06. Elanco raised its 2026 innovation revenue target to $1.15 billion and targets a year-end net leverage ratio of 3.1x–3.3x, down from 3.6x at December 31, 2025.
Dodge & Cox filed an amended Schedule 13G reporting a large passive ownership stake in Elanco Animal Health Incorporated. The firm beneficially owns 79,084,305 Elanco common shares, representing 15.9% of the class, with sole voting power over 75,198,905 shares and sole dispositive power over the full 79,084,305 shares.
The filing notes that Dodge & Cox’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds from these securities. The Dodge & Cox Stock Fund alone holds 53,122,900 Elanco shares, or 10.7% of the class. Dodge & Cox certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Elanco.
Elanco Animal Health executive Robert M. VanHimbergen, EVP and CFO, reported a compensation-related grant of deferred stock units. On 02/06/2026 he acquired 7.5552 deferred stock units at $25.2 each, bringing his beneficially owned deferred stock units to 23.4702.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after termination of employment or in a specified future year under the company’s Executive Deferral and Stock Match Plan.
Elanco Animal Health Inc. reported an insider equity award for its President, CEO and Director, Jeffrey N. Simmons, on February 6, 2026. He acquired 109.8905 deferred stock units at $25.2 per unit, bringing his directly held deferred stock units to 19,068.9056.
Each deferred stock unit represents the right to receive one share of Elanco common stock or the cash equivalent. These units settle in cash or shares after employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan.